Jiangnan Zhao

Jiangnan Zhao

Auto-generated profile, based on publicly available information

Jiangnan Zhao

Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China; Zhejiang Key Laboratory of Precision Diagnosis and Treatment for Lung Cancer, Yiwu, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2025 in Cancer Letters
Verified
Journal Article
Closed access
JZJiangnan Zhao
Jiangnan Zhao
MSMo Shen
Mo Shen
XXXia Xu
Xia Xu
JSji shunxian
ji shunxian
SXShumin Xu
Shumin Xu
KWKai Wang
Kai Wang

5 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JZJiangnan Zhao
Jiangnan Zhao
LDLiren Ding
Liren Ding
JWJiaji Wu
Jiaji Wu
JYJianghao Yu
Jianghao Yu
SCSiyang Chen
Siyang Chen
KWKai Wang
Kai Wang
Background: The widespread occurrence of chronic obstructive pulmonary disease (COPD) significantly complicates the management of lung cancer (LC). Patients suffering from both LC and COPD generally have a poor prognosis and limited effectiveness from conventional therapies, yet they often respond well to immunotherapy. This study aims to characterize the unique tumor microenvironment (TME) of COPD-associated LC (COPD-LC) using multi-omics approaches and to elucidate the mechanisms influencing immunotherapy efficacy.Methods: We performed single‑cell RNA sequencing on tumor and adjacent normal tissues from 11 non‑small cell lung cancer patients (6 with COPD, 5 without), generating a single‑cell atlas of >200,000 cells. These data were integrated with spatial transcriptomics, mass spectrometry‑based proteomics, TCGA data mining, and functional in vitro experiments to systematically map the TME cellular landscape, cell‑cell interactions, and immune regulatory mechanisms in COPD-LC.Findings: Our research identified a distinct subset of CXCL12+ cancer-associated fibroblasts (CAFs) characterized by a heightened stromal signature. These specialized CAFs mediate immunosuppressive effects within the tumor microenvironment of LC patients with comorbid COPD through CXCL12-CXCR4 axis-mediated modulation of CD8+ T cell function. Spatial transcriptomics and multiplex immunofluorescence confirmed colocalization of CXCL12⁺ CAFs with CXCR4⁺ CD8⁺ T cells. SPP1⁺ tumor‑associated macrophages (TAMs) were significantly less abundant in COPD-LC compared to non‑COPD-LC, and this reduction was regulated by the hypoxia‑SPI1 signaling axis. SPP1⁺ TAMs promoted terminal exhaustion of CD8⁺ T cells, whereas in COPD patients CD8⁺ T cells remained in a more progenitor exhaustion state. In vitro assays demonstrated that CXCL12 reduced CD8⁺ T cell effector function (decreased TNF‑α, IFN‑γ, GZMB), while SPP1 upregulated exhaustion markers (PD‑1, TIM‑3) on CD8⁺ T cells.Interpretation: Our results highlight the specific characteristics of the TME that are linked to poor prognosis and altered sensitivity to immunotherapy in COPD-LC, offering a basis for prioritizing treatment strategies to improve therapeutic outcomes.